HER2-negative Breast Cancer Clinical Trials in Nashville, Tennessee
7 recruitingNashville, Tennessee
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Metastatic Breast CancerHR+/HER2-negative Breast Cancer
SynDevRx, Inc.52 enrolled10 locationsNCT05455619
Recruiting
Phase 1
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
HR+/HER2-negative Breast Cancer
Totus Medicines241 enrolled18 locationsNCT05683418
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+6 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 2
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Breast CancerMetastatic Breast CancerHER2-low Breast Cancer+1 more
Ana C Garrido-Castro, MD357 enrolled11 locationsNCT06533826
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 1
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Metastatic Breast CancerHER2-negative Breast Cancer
University of Texas Southwestern Medical Center30 enrolled7 locationsNCT05029999
Recruiting
Phase 2
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Breast CancerHER2-negative Breast CancerTNBC - Triple-Negative Breast Cancer
Processa Pharmaceuticals90 enrolled13 locationsNCT06568692